President-elect Trump selected Jay Bhattacharya, Stanford professor and Covid-19 lockdown critic, to lead NIH, and Jim ...

Axsome Therapeutics’ narcolepsy drug AXS-12 hit the primary endpoint in its Phase 3 ENCORE trial, showing a statistically ...

Sarepta Therapeutics and Arrowhead Pharmaceuticals teamed up on an siRNA partnership that has one of the biggest promises of ...

Alladapt Immunotherapeutics, a well-financed biotech working in the food allergy field, shut down following talks with the ...

FDA extends review of Soleno Therapeutics' diazoxide choline extended-release tablets for Prader-Willi syndrome by three ...

Aviceda seeks $200M for AVD-104 trial, Nerviano reacquires NMS-293 from Merck KGaA, MaaT Pharma reports positive Phase 1b ALS drug data, Secretome raises $20.4M, 35Pharma secures $35M Series C, ...

Amgen’s long-anticipated weight loss data are here, with MariTide spurring an average of 20% weight loss after one year for ...

Roche is acquiring its cell therapy and genomic medicines partner Poseida Therapeutics, the companies said Tuesday morning.

Roche's tiragolumab failed to meet overall survival endpoint in Phase 3 SKYSCRAPER-01 trial when combined with Tecentriq for ...

JPMorgan's Morgan Health co-led an $80 million investment in Cortica, an autism care provider, marking its seventh investment ...

Now that President-elect Donald Trump has made his choice for FDA commissioner, reactions and analysis are pouring in from biopharma executives and former staffers who know the agency’s inner workings ...

Bristol Myers Squibb's cost-cutting initiative will lead to additional layoffs in Lawrenceville, NJ, the company revealed ...